CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

NASDAQ:CTMX • US23284F1057

5.595 USD
+0.17 (+3.04%)
Last: Feb 23, 2026, 03:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

CTMX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. CTMX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CTMX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • CTMX had positive earnings in the past year.
  • CTMX had a negative operating cash flow in the past year.
  • CTMX had negative earnings in 4 of the past 5 years.
  • CTMX had negative operating cash flow in 4 of the past 5 years.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • CTMX has a better Return On Assets (17.70%) than 96.35% of its industry peers.
  • CTMX's Return On Equity of 26.09% is amongst the best of the industry. CTMX outperforms 96.93% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 15.67%, CTMX belongs to the top of the industry, outperforming 96.16% of the companies in the same industry.
Industry RankSector Rank
ROA 17.7%
ROE 26.09%
ROIC 15.67%
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K

1.3 Margins

  • Looking at the Profit Margin, with a value of 24.66%, CTMX belongs to the top of the industry, outperforming 94.82% of the companies in the same industry.
  • CTMX's Operating Margin of 20.46% is amongst the best of the industry. CTMX outperforms 94.63% of its industry peers.
Industry RankSector Rank
OM 20.46%
PM (TTM) 24.66%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • CTMX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • CTMX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CTMX has been increased compared to 5 years ago.
  • CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • CTMX has an Altman-Z score of 6.84. This indicates that CTMX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.84, CTMX is in the better half of the industry, outperforming 76.97% of the companies in the same industry.
  • There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.84
ROIC/WACC1.8
WACC8.72%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 3.64 indicates that CTMX has no problem at all paying its short term obligations.
  • CTMX has a Current ratio (3.64) which is in line with its industry peers.
  • A Quick Ratio of 3.64 indicates that CTMX has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.64, CTMX perfoms like the industry average, outperforming 46.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.64
Quick Ratio 3.64
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CTMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 140.59%, which is quite impressive.
  • Looking at the last year, CTMX shows a very negative growth in Revenue. The Revenue has decreased by -10.26% in the last year.
  • CTMX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.15% yearly.
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%

3.2 Future

  • Based on estimates for the next years, CTMX will show a very negative growth in Earnings Per Share. The EPS will decrease by -28.79% on average per year.
  • Based on estimates for the next years, CTMX will show a small growth in Revenue. The Revenue will grow by 2.57% on average per year.
EPS Next Y-105.9%
EPS Next 2Y-73.47%
EPS Next 3Y-44.25%
EPS Next 5Y-28.79%
Revenue Next Year-31.35%
Revenue Next 2Y-49.49%
Revenue Next 3Y-33.2%
Revenue Next 5Y2.57%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.65, which indicates a correct valuation of CTMX.
  • Based on the Price/Earnings ratio, CTMX is valued cheaper than 97.12% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, CTMX is valued a bit cheaper.
  • CTMX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 13.65
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • CTMX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CTMX is cheaper than 93.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.2
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • CTMX's earnings are expected to decrease with -44.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-73.47%
EPS Next 3Y-44.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CTMX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (2/23/2026, 3:11:46 PM)

5.595

+0.17 (+3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners77.94%
Inst Owner Change3.86%
Ins Owners0.53%
Ins Owner Change8.88%
Market Cap948.02M
Revenue(TTM)113.63M
Net Income(TTM)28.02M
Analysts85.33
Price Target8.67 (54.96%)
Short Float %9.89%
Short Ratio4.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.22%
Min EPS beat(2)-74.27%
Max EPS beat(2)98.72%
EPS beat(4)3
Avg EPS beat(4)88.28%
Min EPS beat(4)-74.27%
Max EPS beat(4)215.22%
EPS beat(8)7
Avg EPS beat(8)121.73%
EPS beat(12)10
Avg EPS beat(12)96.64%
EPS beat(16)11
Avg EPS beat(16)69.24%
Revenue beat(2)1
Avg Revenue beat(2)-12.98%
Min Revenue beat(2)-49.71%
Max Revenue beat(2)23.76%
Revenue beat(4)3
Avg Revenue beat(4)32.06%
Min Revenue beat(4)-49.71%
Max Revenue beat(4)92.34%
Revenue beat(8)7
Avg Revenue beat(8)44.02%
Revenue beat(12)10
Avg Revenue beat(12)36.04%
Revenue beat(16)10
Avg Revenue beat(16)9.74%
PT rev (1m)20.2%
PT rev (3m)38.37%
EPS NQ rev (1m)-13.46%
EPS NQ rev (3m)-72.25%
EPS NY rev (1m)-14.74%
EPS NY rev (3m)-176.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.43%
Valuation
Industry RankSector Rank
PE 13.65
Fwd PE N/A
P/S 8.34
P/FCF N/A
P/OCF N/A
P/B 8.83
P/tB 8.95
EV/EBITDA 27.2
EPS(TTM)0.41
EY7.33%
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.67
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.42
Profitability
Industry RankSector Rank
ROA 17.7%
ROE 26.09%
ROCE 19.83%
ROIC 15.67%
ROICexc N/A
ROICexgc N/A
OM 20.46%
PM (TTM) 24.66%
GM N/A
FCFM N/A
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 7.74%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.64
Quick Ratio 3.64
Altman-Z 6.84
F-Score5
WACC8.72%
ROIC/WACC1.8
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
EPS Next Y-105.9%
EPS Next 2Y-73.47%
EPS Next 3Y-44.25%
EPS Next 5Y-28.79%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%
Revenue Next Year-31.35%
Revenue Next 2Y-49.49%
Revenue Next 3Y-33.2%
Revenue Next 5Y2.57%
EBIT growth 1Y246.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.27%
EBIT Next 3Y-102.03%
EBIT Next 5YN/A
FCF growth 1Y-99.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.53%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOMX THERAPEUTICS INC / CTMX FAQ

What is the fundamental rating for CTMX stock?

ChartMill assigns a fundamental rating of 4 / 10 to CTMX.


What is the valuation status for CTMX stock?

ChartMill assigns a valuation rating of 3 / 10 to CYTOMX THERAPEUTICS INC (CTMX). This can be considered as Overvalued.


What is the profitability of CTMX stock?

CYTOMX THERAPEUTICS INC (CTMX) has a profitability rating of 4 / 10.


What is the financial health of CYTOMX THERAPEUTICS INC (CTMX) stock?

The financial health rating of CYTOMX THERAPEUTICS INC (CTMX) is 7 / 10.


What is the expected EPS growth for CYTOMX THERAPEUTICS INC (CTMX) stock?

The Earnings per Share (EPS) of CYTOMX THERAPEUTICS INC (CTMX) is expected to decline by -105.9% in the next year.